Marshall Wace
PTGX icon

Marshall Wace’s Protagonist Therapeutics PTGX Stock Holding History

Marshall Wace’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4M Sell
109,017
-519,058
-83% -$54.2M 0.01% 913
2026
Q1 		$66.2M Sell
628,075
-396,850
-39% -$35.1M 0.07% 271
2025
Q4 		$89.5M Sell
1,024,925
-60,639
-6% -$4.96M 0.08% 190
2025
Q3 		$72.1M Buy
+1,085,564
New +$61.7M 0.07% 238
2025
Q1 		– Sell
-19,716
Closed -$761K – 3007
2024
Q4 		$761K Sell
19,716
-295,657
-94% -$12.9M ﹤0.01% 1864
2024
Q3 		$14.2M Sell
315,373
-256,804
-45% -$10.4M 0.02% 627
2024
Q2 		$19.8M Sell
572,177
-404,716
-41% -$11.9M 0.03% 502
2024
Q1 		$28.3M Buy
976,893
+834,423
+586% +$22.7M 0.04% 397
2023
Q4 		$3.27M Buy
142,470
+120,723
+555% +$2.11M 0.01% 1052
2023
Q3 		$363K Sell
21,747
-142,753
-87% -$2.77M ﹤0.01% 1817
2023
Q2 		$4.54M Sell
164,500
-1,201,580
-88% -$30.1M 0.01% 1058
2023
Q1 		$31.4M Sell
1,366,080
-88,366
-6% -$1.48M 0.07% 313
2022
Q4 		$15.9M Buy
1,454,446
+639,720
+79% +$5.4M 0.04% 564
2022
Q3 		$6.87M Buy
814,726
+350,669
+76% +$3.32M 0.02% 1154
2022
Q2 		$3.67M Buy
+464,057
New +$5.61M 0.01% 1575
2021
Q2 		– Sell
-86,691
Closed -$2.25M – 3002
2021
Q1 		$2.25M Sell
86,691
-30,103
-26% -$762K 0.01% 1265
2020
Q4 		$2.35M Buy
+116,794
New +$2.51M 0.01% 883
2019
Q3 		– Sell
-17,799
Closed -$216K – 1887
2019
Q2 		$216K Buy
+17,799
New +$197K ﹤0.01% 1235

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Marshall Wace's PTGX Position: Q2 2026 in Review

Marshall Wace reduced its Protagonist Therapeutics (PTGX) stake by 83% in Q2 2026, selling an estimated $54.2M and leaving 109,017 shares worth $13.4M. The position accounts for 0.01% of the portfolio, ranked #913.

Marshall Wace first reported a position in PTGX in Q2 2019 and has held it in 18 quarters since. The position peaked at $89.5M in Q4 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Marshall Wace held 109,017 shares of Protagonist Therapeutics worth $13.4M as of Q2 2026.
  • Marshall Wace sold 519,058 Protagonist Therapeutics shares in Q2 2026, an estimated $54.2M.
  • Protagonist Therapeutics made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #913 holding.
  • Marshall Wace first reported a position in Protagonist Therapeutics in Q2 2019 and has held it in 18 quarters since.
  • Marshall Wace's Protagonist Therapeutics position peaked at $89.5M in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.